MB
KALV

MPM BioImpact’s KalVista Pharmaceuticals KALV Stock Holding History

MPM BioImpact’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-896,915
Closed -$10.4M – 49
2024
Q3 		$10.4M Buy
896,915
+14,978
+2% +$188K 1.56% 22
2024
Q2 		$10.4M Buy
881,937
+121,215
+16% +$1.41M 1.61% 23
2024
Q1 		$9.02M Buy
+760,722
New +$10.1M 1.45% 26
2023
Q4 		– Sell
-577,958
Closed -$5.57M – 33
2023
Q3 		$5.57M Sell
577,958
-183,580
-24% -$1.88M 1.49% 23
2023
Q2 		$6.85M Buy
+761,538
New +$7.02M 1.38% 22

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

MPM BioImpact's KALV Position: Q4 2024 in Review

MPM BioImpact sold out of KalVista Pharmaceuticals (KALV) in Q4 2024, closing a stake of 896,915 shares — an estimated $10.4M sold.

MPM BioImpact first reported a position in KALV in Q2 2023 and held it in 5 quarters. The position peaked at $10.4M in Q2 2024. 130 funds tracked by Wall St. Rank hold KALV as of Q4 2024.

  • MPM BioImpact reported no remaining KalVista Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • MPM BioImpact sold 896,915 KalVista Pharmaceuticals shares in Q4 2024, an estimated $10.4M.
  • MPM BioImpact first reported a position in KalVista Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • MPM BioImpact's KalVista Pharmaceuticals position peaked at $10.4M in Q2 2024.
  • 130 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2024.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.